NCT06902545 2026-03-11A Study to Observe the Safety of VYLOY (Zolbetuximab) in People in South Korea With Gastric or Gastroesophageal Junction Cancer.Astellas Pharma IncRecruiting377 enrolled
NCT03504397 2026-02-13SpotlightAstellas Pharma IncPhase 3 Active not recruiting565 enrolled 63 charts 1 FDA
NCT03653507 2026-02-06GLOWAstellas Pharma IncPhase 3 Active not recruiting507 enrolled 65 charts 1 FDA
NCT03528629 2024-12-02A Study of IMAB362 in Japanese Subjects With Locally Advanced or Metastatic Gastric or Gastro-esophageal Junction (GEJ) AdenocarcinomaAstellas Pharma IncPhase NA Completed18 enrolled